Drug Sales Trends for brimonidine

Payment Methods and Pharmacy Types for brimonidine (2011)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$306,355
INSIDE ANOTHER STORE	$16,288,149

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	5,255
INSIDE ANOTHER STORE	177,574

Revenues by Payment Method

Payment Method	Revenues
MEDICAID	$1,665,652
MEDICARE	$35,983,897

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for brimonidine

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
BRIMONIDINE			2022
BRIMONIDINE			2021
BRIMONIDINE			2020
BRIMONIDINE			2019
BRIMONIDINE			2018
BRIMONIDINE			2017

Brimonidine Market Analysis, Sales Forecast, Patent Status, and Generic Competition

Last updated: September 3, 2026

Brimonidine is a mature ophthalmic and dermatologic drug with two distinct commercial markets: glaucoma treatment and facial erythema treatment. Generic ophthalmic brimonidine dominates volume, while Galderma’s Mirvaso retains the principal branded position in topical dermatology. The combined global market is best modeled at approximately $400 million in 2024 net sales, with low-single-digit growth through 2029 under the base case. Value growth is constrained by generic erosion, low prices, and limited clinical differentiation.

What is brimonidine used for?

Brimonidine is an alpha-2 adrenergic receptor agonist approved in several formulations.

Product category	Active ingredient	Principal indication	Main commercial products
Ophthalmic solution	Brimonidine tartrate	Lowering intraocular pressure in open-angle glaucoma or ocular hypertension	Generic brimonidine, Alphagan P
Ophthalmic combination	Brimonidine tartrate plus timolol	Glaucoma and ocular hypertension	Combigan, generic equivalents
Topical gel	Brimonidine tartrate	Persistent facial erythema associated with rosacea	Mirvaso
Fixed-dose combinations	Brimonidine with other ophthalmic agents	Glaucoma	Regional products and development candidates

The ophthalmic market is substantially larger in treated-patient volume than the dermatology market. The dermatology market has higher branded pricing and greater sensitivity to reimbursement, cosmetic use patterns, and patient persistence.

The FDA approved brimonidine ophthalmic products for intraocular-pressure reduction, while Mirvaso was approved in 2013 for topical treatment of persistent facial erythema associated with rosacea [1,2].

How large is the brimonidine market?

The market has no single reliable public sales figure because brimonidine is sold across generic, branded, combination, prescription, and international channels. Public company reports generally do not disclose standalone revenue for generic brimonidine or Mirvaso.

Estimated 2024 market by segment

Segment	Estimated 2024 global net sales	Market structure	2024-2029 outlook
Generic brimonidine ophthalmic	$150 million-$220 million	Fragmented generic supply	Stable to declining
Alphagan P and branded ophthalmic products	$20 million-$40 million	Residual branded share	Declining
Brimonidine-timolol products	$100 million-$150 million	Generic and branded competition	Low growth or decline
Mirvaso and topical brimonidine	$80 million-$120 million	Branded dermatology market	Low-single-digit growth
Other international and combination products	$30 million-$70 million	Country-specific markets	Mixed
Total brimonidine-related market	$380 million-$600 million	Mature, multi-product market	Low-single-digit growth

The central estimate for the combined market is approximately $460 million in 2024. This estimate includes products containing brimonidine and excludes unrelated alpha-2 agonists such as apraclonidine.

A narrower definition covering brimonidine monotherapy only would produce a materially smaller market, likely between $230 million and $330 million globally.

What are the brimonidine sales projections through 2029?

The forecast below uses a 2024 central market estimate of $460 million and applies segment-specific assumptions. It represents modeled net sales, not reported company revenue.

Base-case global projection

Year	Estimated market sales	Annual growth
2024	$460 million	Base year
2025	$469 million	2.0%
2026	$480 million	2.3%
2027	$491 million	2.3%
2028	$503 million	2.4%
2029	$515 million	2.4%

The forecast assumes:

• Generic ophthalmic volume remains stable, with continuing price erosion.
• Brimonidine-timolol combinations offset some monotherapy decline.
• Mirvaso grows modestly through dermatology prescribing, cosmetic demand, and international expansion.
• No major new indication materially expands the patient population.
• No large-scale manufacturing interruption affects generic supply.
• Branded ophthalmic products continue losing share to lower-cost alternatives.

Scenario analysis

Scenario	2029 market sales	Implied 2024-2029 CAGR	Principal assumptions
Downside	$390 million	-3.3%	Faster generic price erosion, weak Mirvaso persistence, limited international growth
Base case	$515 million	2.3%	Stable ophthalmic volume and modest topical growth
Upside	$650 million	7.2%	Stronger dermatology demand, improved adherence, expanded combination use

The upside case requires commercial expansion rather than a major scientific breakthrough. Brimonidine is already well established, and the principal growth opportunity is improved market execution in dermatology and fixed-dose ophthalmic combinations.

Which companies sell brimonidine products?

The competitive market is fragmented.

Major commercial participants

Company	Product or role	Market exposure
Galderma	Mirvaso topical gel	Branded rosacea treatment
AbbVie	Alphagan P and Combigan legacy products	Branded ophthalmology, reduced by generic competition
Sandoz	Generic ophthalmic products in several markets	Generic glaucoma
Apotex	Generic brimonidine and ophthalmic products	North American generic market
Bausch + Lomb	Ophthalmic generics and glaucoma portfolio	Ophthalmology distribution
Akorn and other generic suppliers	Brimonidine ophthalmic products	U.S. and international generic supply
Regional manufacturers	Local brimonidine and combination products	Europe, Asia, Latin America, and other markets

Product ownership can vary by jurisdiction, and generic suppliers may change through licensing, acquisition, or supply agreements.

Galderma is the principal commercial company associated with Mirvaso. AbbVie inherited Alphagan P and Combigan through its acquisition of Allergan, although the economic value of these products has been reduced by generic competition and the maturity of their patent estates [3].

What is the FDA regulatory status of brimonidine?

Brimonidine ophthalmic products are approved prescription medicines. The original glaucoma indication is mature and supported by extensive clinical use.

Mirvaso is an FDA-approved topical gel containing brimonidine tartrate for persistent facial erythema associated with rosacea. Its label includes warnings relating to systemic cardiovascular effects, accidental transfer to children, and worsening erythema or rebound redness in some patients [2].

Regulatory status by product

Product	FDA status	Regulatory pathway	Market condition
Brimonidine ophthalmic solution	Approved	NDA and ANDA pathways	Generic competition
Brimonidine-timolol ophthalmic solution	Approved	NDA and ANDA pathways	Generic and branded competition
Mirvaso gel	Approved	NDA	Branded topical market
Biosimilar pathway	Not applicable	Small-molecule drug framework	No biosimilar exposure

Brimonidine is a small-molecule drug. Biosimilar risk does not apply. Generic substitution under the Abbreviated New Drug Application pathway is the central U.S. regulatory risk for ophthalmic products.

When does brimonidine lose exclusivity?

Brimonidine’s principal glaucoma patents are generally expired or commercially weakened by generic competition. The practical loss of exclusivity occurred years ago for ophthalmic monotherapy.

The commercial position is different for Mirvaso. Topical rosacea protection depends on product-specific patents, formulation claims, method-of-use claims, pediatric exclusivity, regulatory exclusivity, and the timing of any ANDA challenge. FDA Orange Book listings and USPTO records must be reviewed together because an Orange Book-listed patent does not guarantee enforceability or a successful injunction [4,5].

Exclusivity assessment

Product	Exclusivity position	Generic entry risk
Generic brimonidine ophthalmic	No meaningful exclusivity	Already genericized
Alphagan P	Legacy branded product	High
Combigan	Legacy combination product	High, with formulation and equivalence issues
Mirvaso	Product-specific patent and formulation exposure	Moderate to high over time

Mirvaso’s commercial protection is more dependent on formulation and delivery characteristics than on the basic brimonidine molecule. The active ingredient itself is old and does not provide meaningful composition-of-matter protection.

What patents protect Mirvaso and other brimonidine products?

The strongest potential protection for topical brimonidine is likely to involve:

• Gel composition and excipient selection.
• Concentration and viscosity.
• Controlled or sustained delivery.
• Treatment of persistent facial erythema.
• Dosing and application instructions.
• Reduced systemic absorption.
• Stability and manufacturing processes.

Ophthalmic products may rely on:

• Preservative systems.
• Purity and impurity controls.
• Container-closure systems.
• Concentration ranges.
• Combination formulations with timolol.
• Dosing methods and treatment regimens.

The basic brimonidine molecule is not a strong source of current exclusivity because it has been commercially available for decades. Formulation patents can delay direct substitution, but their scope is narrower and more vulnerable to design-around strategies.

Patent strength by product

Product	Composition-of-matter strength	Formulation strength	Method-of-use strength	Overall commercial protection
Generic brimonidine ophthalmic	Very low	Low	Low	Weak
Alphagan P	Expired or weak legacy protection	Low to moderate	Low	Weak
Combigan	Expired or weakened core protection	Moderate	Moderate	Moderate historically
Mirvaso	Low for active ingredient	Moderate to strong	Moderate	Stronger than ophthalmic monotherapy

The relevant diligence question is not whether brimonidine has patents. It is whether a particular patent is unexpired, listed for the relevant product, enforceable, and difficult to design around.

What Paragraph IV challenges affect brimonidine?

Paragraph IV litigation is most relevant to Mirvaso and other branded topical products with remaining Orange Book-listed patents. Generic ophthalmic brimonidine has already experienced broad generic entry, so future Paragraph IV activity is less commercially significant for the basic monotherapy market.

A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. The NDA holder can file an infringement action within 45 days, potentially triggering a 30-month stay of FDA approval under the Hatch-Waxman framework [6].

Litigation exposure

Product	Paragraph IV relevance	Likely dispute focus
Brimonidine ophthalmic monotherapy	Low	Residual formulation or supplier-specific patents
Brimonidine-timolol	Moderate	Bioequivalence, formulation, and combination claims
Mirvaso	High relative to other brimonidine products	Gel composition, concentration, topical performance, method of use

Public litigation records should be checked in the U.S. District Court system and FDA Orange Book before relying on any claimed launch date. A patent settlement can permit an authorized or licensed generic launch before full patent expiration, making the nominal patent date a poor proxy for actual market entry.

What formulation patents protect brimonidine?

Formulation protection is commercially important because brimonidine is a low-complexity active ingredient with limited chemical novelty.

Ophthalmic formulations

Ophthalmic formulation claims may cover:

• Low-concentration brimonidine solutions.
• Reduced-preservative or preservative-free delivery.
• Polyvinyl alcohol, borate, or related excipient systems.
• Container systems that preserve sterility and stability.
• Fixed-dose combinations with timolol.

These claims can support a branded product, but generic applicants can seek approval through alternative excipients or packaging if therapeutic equivalence is demonstrated.

Topical formulations

Mirvaso’s formulation value is tied to the ability to deliver brimonidine to facial skin while limiting systemic exposure and reducing adverse redness reactions. Formulation differentiation can support premium pricing and physician preference, but topical generic approval and substitution depend on the applicable FDA requirements for pharmaceutical equivalence and therapeutic equivalence.

What generic entry risks exist for brimonidine?

Generic entry is the primary risk in the ophthalmic segment. The risk is already realized for standard brimonidine ophthalmic solution.

Generic risk by segment

Segment	Current risk	Expected impact
Brimonidine ophthalmic solution	Very high	Low prices and declining branded share
Brimonidine-timolol	High	Volume retention but margin compression
Alphagan P	High	Continued substitution
Mirvaso	Moderate to high	Potential price erosion if an approved generic enters
Novel delivery systems	Variable	Depends on patent scope and FDA equivalence pathway

Mirvaso has greater near-term strategic value than generic ophthalmic brimonidine because dermatology pricing is higher and the product has stronger brand recognition. A successful generic launch would likely reduce price and market share, although physician prescribing and patient preference could preserve part of the branded market.

How does brimonidine compare with competing glaucoma drugs?

Brimonidine competes with prostaglandin analogs, beta blockers, carbonic anhydrase inhibitors, rho kinase inhibitors, and fixed-dose combinations.

Drug class	Main advantage	Main limitation relative to brimonidine
Prostaglandin analogs	Strong intraocular-pressure reduction and once-daily dosing	Ocular pigmentation and eyelash-related effects
Beta blockers	Established efficacy and low cost	Cardiopulmonary contraindications
Carbonic anhydrase inhibitors	Useful adjunctive therapy	More frequent dosing and tolerability issues
Rho kinase inhibitors	Newer mechanism	Hyperemia and higher cost
Brimonidine	Useful adjunctive pressure reduction and broad generic availability	Allergic reactions, fatigue, dry mouth, and multiple daily dosing

Brimonidine is often used as adjunctive therapy rather than as the sole first-line treatment. Its role remains durable because it is inexpensive, familiar, and available in combination products.

How does Mirvaso compare with competing rosacea treatments?

Mirvaso occupies a specific position in the rosacea market because it targets persistent facial erythema rather than inflammatory papules and pustules.

Product class	Primary target	Competitive relationship
Mirvaso	Persistent facial erythema	Direct brimonidine competitor set
Oxymetazoline cream	Persistent facial erythema	Closest branded topical competitor
Metronidazole	Inflammatory rosacea lesions	Indirect
Azelaic acid	Inflammatory lesions and erythema	Indirect
Ivermectin	Inflammatory lesions	Indirect
Laser and light therapy	Vascular erythema	Procedure-based alternative

The main commercial risk to Mirvaso is not only generic entry. It is substitution by oxymetazoline, laser therapy, and other rosacea treatments that improve overall patient satisfaction.

What licensing deals and partnerships affect brimonidine?

Brimonidine has been commercialized through licensing, distribution, and generic supply arrangements across multiple jurisdictions. Product-level revenue is often reported within broader ophthalmology or dermatology portfolios rather than separately.

The most visible ownership transaction is AbbVie’s acquisition of Allergan, which transferred the legacy Alphagan and Combigan portfolio to AbbVie [3]. Mirvaso remains associated with Galderma’s dermatology portfolio.

The commercial significance of licensing is highest in:

• Regional rights for topical dermatology products.
• Generic supply and authorized-generic arrangements.
• Fixed-dose ophthalmic combinations.
• Manufacturing and distribution agreements.
• Technology transfer for sterile ophthalmic production.

What manufacturing barriers affect brimonidine?

Manufacturing barriers are moderate for the active ingredient and higher for sterile ophthalmic products.

Key barriers

1. Sterile filling and aseptic manufacturing.
2. Container-closure integrity.
3. Preservative compatibility.
4. Impurity and degradation control.
5. Batch consistency for topical gels.
6. Bioequivalence or comparative-performance testing.
7. Regulatory approval across multiple jurisdictions.

The active pharmaceutical ingredient is not considered a major manufacturing bottleneck in normal conditions. Supply risk is more likely to arise from a limited number of qualified sterile manufacturing sites, inspection findings, or packaging failures.

What is the investment outlook for brimonidine?

Brimonidine is a cash-generative but low-growth market. The best investment characteristics are concentrated in branded dermatology, differentiated delivery systems, and combination ophthalmic products.

Revenue exposure

• Generic ophthalmic products: high volume, low margins.
• Legacy branded ophthalmic products: declining revenue and limited pricing power.
• Mirvaso: lower volume but higher revenue per patient.
• Combination products: stronger retention than monotherapy where adherence and convenience support prescribing.
• New formulations: potentially attractive, but dependent on patent durability and clinical differentiation.

The base-case market forecast of $515 million in 2029 implies modest expansion in total value, not a return to branded-monopoly economics. Investors should value Mirvaso and differentiated combinations separately from commodity brimonidine ophthalmic products.

Key Takeaways

• Brimonidine is a mature drug with separate glaucoma and rosacea markets.
• The combined global market is estimated at approximately $460 million in 2024.
• Base-case sales reach about $515 million by 2029, representing a 2.3% CAGR.
• Generic ophthalmic brimonidine already faces severe price and share pressure.
• Mirvaso has the strongest remaining commercial position because topical dermatology pricing is higher.
• Formulation, delivery, and method-of-use patents matter more than the old brimonidine molecule.
• Biosimilar risk does not apply because brimonidine is a small molecule.
• Paragraph IV exposure is more relevant to Mirvaso and combination products than to standard ophthalmic monotherapy.
• Manufacturing risk is moderate, with sterile ophthalmic production creating the main operational barrier.
• The market is defensive and cash-oriented rather than a high-growth pharmaceutical opportunity.

FAQs

Is brimonidine still a profitable drug?

Yes, but profitability is concentrated in branded topical products and selected combination products. Generic ophthalmic brimonidine is profitable mainly through manufacturing scale and distribution efficiency.

Does Mirvaso have generic competition?

Mirvaso faces generic-entry risk through the ANDA pathway. The timing and commercial effect depend on unexpired Orange Book-listed patents, litigation outcomes, FDA approval, and any settlement terms.

Is brimonidine included in the FDA Orange Book?

FDA-approved brimonidine products and relevant listed patents may appear in the Orange Book by product and dosage form. Listings must be reviewed separately for ophthalmic solutions, combination products, and topical gel products [4].

What is the largest commercial use of brimonidine?

Glaucoma and ocular-hypertension treatment is the largest use by patient volume. Mirvaso is more commercially differentiated because it serves the prescription dermatology market.

Can brimonidine sales grow despite generic competition?

Yes. Growth can come from topical rosacea treatment, fixed-dose combinations, international markets, and improved patient persistence. Standard ophthalmic monotherapy is unlikely to generate sustained high growth.

References

1. U.S. Food and Drug Administration. (1996). Alphagan ophthalmic solution prescribing information. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (2013). Mirvaso (brimonidine tartrate) topical gel prescribing information. FDA Drugs@FDA.

3. AbbVie Inc. (2020). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. AbbVie.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System. USPTO.

6. U.S. Code. (2024). 21 U.S.C. § 355: New drugs and antibiotics. Legal Information Institute, Cornell Law School.